A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Daclatasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms NEPTUNE
- Sponsors Janssen R&D Ireland
- 16 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov
- 18 May 2015 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov
- 18 May 2015 Planned initiation date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov